Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Affymetrix and Asuragen have announced an agreement to license, develop and manufacture in vitro transcription reagent kits for clinical molecular diagnostic applications.
Subscribe to our email newsletter
The new in vitro transcription (IVT) reagent kits developed and manufactured by Asuragen will enable Affymetrix to deliver a complete solution to its molecular diagnostic partners.
The products will be optimally designed for clinical use and will be configured for use with the GeneChip system 3000Dx. This is said to be the only available diagnostic microarray platform that has earned 510(k) clearance from the FDA and the CE mark from the European Union.
Matt Winkler, CEO and chief scientific officer of Asuragen, said: “These new reagent kits will facilitate more adoption of Affymetrix microarray technology by significantly improving workflow in the clinical diagnostic laboratory.”